CAR T-cell Therapy and Bispecific Antibodies: Frontiers in Cancer Immunotherapy

Thu, May 24, 2018 2:30 PM EDT{LOCAL_TZ}

CAR T-cell Therapy and Bispecific Antibodies: Frontiers in Cancer Immunotherapy

Cancers are the most heterogenous group of diseases affecting humans. Multiple compensating pathways work to promote disease progression. Various immunotherapies have shown anticancer promise, but the their targeted nature limits the scope of their action and applicability. CAR T-cell therapy and bispecific antibodies are two approaches that have addressed the targeting of more than one epitope, the re-directing of T lymphocytes to kill tumor cells, and the improvement of efficacy in solid tumor types. For a closer look at the design, development, and success of CAR T-cell therapy and bispecific antibodies, The Scientist is bringing together a panel of experts to discuss their research and share insights into the potential these therapeutics hold in the fight against various tumor types. Join us to get your questions answered by our esteemed panel.

Topics to be Covered:
  • Where cancer immunotherapies are living up to their promise, and where they’re falling short
  • The art and science of developing novel immunotherapies

Bruce Levine, PhD
Netter Professor in Cancer Gene Therapy; Founding Director, Clinical Cell & Vaccine Production Facility; Deputy Director, Center for Cellular Immunotherapies;
Department of Pathology & Laboratory Medicine, Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania
John H. Sampson, MD, PhD, MBA, MHSc
Wilkins Professor and Chairman, Department of Neurosurgery
Duke University Medical Center
Luis A. Sanchez Perez, PhD
Assistant Professor, Brain Tumor Immunotherapy Program
Department of Neurosurgery, Duke University Medical Center

close log in form button
Log In Now Not Registered?

close register form button
Register Now Already Registered?